Odyssey Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
ODTX$19.15-0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $80,641 | $41,687 |
| Short-term marketable securities | 245,360 | 139,671 |
| Prepaid expenses and other current assets | 11,800 | 9,298 |
| Total current assets | 337,801 | 190,656 |
| Property and equipment, net | 4,626 | 7,209 |
| Right-of-use assets | 16,137 | 18,804 |
| Goodwill | 14,119 | 14,327 |
| Intangible asset | - | 262 |
| Long-term marketable securities | 60,987 | 35,198 |
| Other non-current assets | 4,430 | 3,332 |
| Total assets | $438,100 | $269,788 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $8,260 | $7,872 |
| Accrued expenses and other current liabilities | 12,309 | 13,392 |
| Lease liabilities, current | 5,532 | 5,211 |
| Total current liabilities | 26,101 | 26,475 |
| Contingent consideration and warrant liability | 18,281 | 6,133 |
| Lease liabilities, non-current | 17,946 | 21,900 |
| Total liabilities | 62,328 | 54,508 |
| Commitments and contingencies (see Note 13) | ||
| Series A convertible preferred stock, $0.0001 par value: no shares and 43,749,045 shares authorized as of September 30, 2026 and December 31, 2025, respectively; and no shares and 43,732,797 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $84,796 as of September 30, 2026 and December 31, 2025, respectively) | - | 216,503 |
| Series B convertible preferred stock, $0.0001 par value: no shares and 26,601,360 shares authorized as of September 30, 2026 and December 31, 2025, respectively; and no shares and 26,601,360 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $66,100 as of September 30, 2026 and December 31, 2025, respectively) | - | 167,765 |
| Series C convertible preferred stock, $0.0001 par value: no shares and 24,901,598 shares authorized as of September 30, 2026 and December 31, 2025, respectively; and no shares and 24,901,598 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $49,065 as of September 30, 2026 and December 31, 2025, respectively) | - | 123,259 |
| Series D convertible preferred stock, $0.0001 par value: no shares and 142,016,823 shares authorized as of September 30, 2026 and December 31, 2025, respectively; and no shares and 141,950,377 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $213,631 as of September 30, 2026 and December 31, 2025, respectively) | - | 196,031 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.0001 par value: 500,000,000 and 365,081,240 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 48,067,433 shares and 2,472,757 shares issued as of September 30, 2026 and December 31, 2025, respectively; 47,940,608 shares and 2,306,207 shares outstanding as of September 30, 2026 and December 31, 2025, respectively | 5 | - |
| Preferred stock, $0.0001 par value: 50,000,000 shares and no shares authorized as of September 30, 2026 and December 31, 2025; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | - | - |
| Additional paid-in capital | 1,089,000 | 79,616 |
| Accumulated deficit | (712,248) | (568,139) |
| Accumulated other comprehensive income (loss) | (985) | 245 |
| Total stockholders’ equity (deficit) | 375,772 | (488,278) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $438,100 | $269,788 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.